BiotechTube

Brolucizumab

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Neovascular Age-related Macular Degeneration

Conditions

Neovascular Age-related Macular Degeneration

Trial Timeline

Oct 15, 2021 → Oct 4, 2023

NCT ID
NCT04774926

About Brolucizumab

Brolucizumab is a approved stage product being developed by Novartis for Neovascular Age-related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT04774926. Target conditions include Neovascular Age-related Macular Degeneration.

What happened to similar drugs?

17 of 20 similar drugs in Neovascular Age-related Macular Degeneration were approved

Approved (17) Terminated (3) Active (3)
✅ranibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅Intraviteal Ranibizumab 0.5mgNovartisApproved
✅RanibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅Ranibizumab + AfliberceptNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT05959304ApprovedActive
NCT04774926ApprovedCompleted
NCT04679935ApprovedCompleted
NCT04697953Phase 3Withdrawn
NCT04764656Pre-clinicalTerminated
NCT04597632Phase 3Completed
NCT04543331Pre-clinicalCompleted
NCT05111743Pre-clinicalCompleted
NCT05082415Pre-clinicalCompleted
NCT05037396Pre-clinicalCompleted

Competing Products

20 competing products in Neovascular Age-related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
35
KHK4951 + Aflibercept InjectionKyowa KirinPhase 2
39
Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab ControlAbbViePhase 3
47
Ranibizumab + Local Steroid + Topical SteroidAbbViePhase 2
39
LucentisNovartisPre-clinical
26
ranibizumabNovartisPhase 3
40
BrolucizumabNovartisPre-clinical
18
ranibizumabNovartisApproved
43
brolucizumab + ranibizumab + afliberceptNovartisPre-clinical
26
BeovuNovartisPre-clinical
26
RanibizumabNovartisPhase 3
40
RanibizumabNovartisApproved
43
Intraviteal Ranibizumab 0.5mgNovartisApproved
43